UK-based Oviva, which offers personalized diet and lifestyle advice via apps, raises $80M Series C led by Sofina and Temasek, bringing total funding to $115M
Context & Ripple Effects
Oviva has nearly quadrupled its disclosed funding since its $21M Series B in early 2020, when it was positioning app-based coaching as a tech-driven approach to Type 2 diabetes treatment across Europe. The new $80M round brings total funding to $115M and adds Temasek alongside lead backer Sofina.
Sofina's involvement repeats a pattern: the firm also led UK fintech Cleo's $80M Series C last year. The raise lands in a crowded but well-funded lane — Zoe's £25M extension at a £209M valuation, Noom's Sequoia-led Series E, and Palta's $100M Series B all landed within the same window, showing investors treating nutrition and lifestyle apps as a scalable category rather than niche wellness.
First-order effects
- Oviva gains the balance sheet to push its clinician-delivered, app-based diet and lifestyle programs deeper into European healthcare systems, moving beyond the Type 2 diabetes beachhead it built on its Series B.
- Sofina now holds parallel positions in two UK-headquartered app companies that both raised $80M Series Cs under its lead — Oviva in clinical nutrition, Cleo in Gen Z finance — concentrating its bets on subscription app models.
Second-order effects
- Zoe, Noom, and Palta face a better-capitalized rival claiming clinical credibility through diabetes care, pressuring them to differentiate either toward direct-to-consumer engagement or toward payer-facing outcomes data of their own.
- Temasek's entry signals sovereign-wealth appetite for European digital health at Series C scale, raising the bar for what later-stage nutrition startups must show to attract comparable strategic capital.
Third-order effects
- If clinical channels keep out-raising pure consumer weight-loss apps, the category splits structurally: reimbursement-backed players like Oviva consolidate toward medical-grade digital therapeutics while DTC brands compete on brand and engagement.
- The pattern also points toward national health systems becoming the decisive distribution channel for diet and lifestyle software, making regulatory approval and payer contracts the moat instead of app-store growth.
The trend: App-based nutrition and lifestyle coaching is bifurcating into clinically validated, payer-facing platforms and consumer wellness brands, with crossover and sovereign investors like Sofina and Temasek funding the clinical end at Series C scale.